Lead Product(s): ISD017
Therapeutic Area: Immunology Product Name: ISD017
Highest Development Status: Undisclosed Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2021
US patent covering the lead candidate ISD017, which uniquely blocks all aspects of STING pathway overactivation in severe systemic lupus erythematosus (SLE) patients.
Lead Product(s): Bispecific antibodies
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Tavotek Biotherapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 25, 2020
The objective of the agreement is to develop a novel first-in-class immune-modulator bispecific antibody for auto-immune and inflammatory-related conditions, using DuoBody® technology, proprietary platform of Genmab A/S of Denmark.